The US FDA has approved Xience Prime, a next generation everolimus eluting coronary stent system for patients with coronary artery disease. According to Abbot Laboratories, this new stent offers doctors a wider range of drug eluting stents which have emanated from the SPIRIT family of trials. The company says that Xience Prime has an improved stent design and a more flexible delivery system compared to the Xience V® Everolimus Eluting Coronary Stent System. It also offers ideal radial strength and more accurate stent placement. The new stent uses the same drug and biocompatible polymer as the Xience V.


  • Two registry arms were assessed:
    • The Core Size arm - Xience Prime stents were used, measuring 8mm to 28mm long and 2.25mm to 4mm in diameter.
    • The Long Lesion arm - Xience Prime stents were used, measuring either 33mm or 38mm long, and 2.5mm and 4mm in diameter.